The Emsella Chair is a revolutionary, non-invasive treatment that uses high-intensity focused electromagnetic (HIFEM) technology to strengthen the pelvic floor muscles. One 28-minute session delivers the equivalent of over 11,000 Kegel exercises, helping improve bladder control, pelvic health, and overall confidence.

Emsella is ideal for women and men who experience:

• Urinary leakage when coughing, sneezing, or exercising
  
• A frequent urge to urinate
  
• A weak pelvic floor after childbirth, surgery, or ageing
  
• Decreased intimate satisfaction due to pelvic floor weakness

It’s also suitable as a preventive measure for those who want to maintain good pelvic floor health.

Not at all. Emsella is completely non-invasive and pain-free. You remain fully clothed during the session and simply sit on the chair. Most patients describe the sensation as mild tingling and pelvic floor muscle contractions.

A typical course is 6 sessions, usually done twice a week for three weeks. Some people notice improvements after just one session, but the best results are achieved over the full course. Maintenance sessions can be scheduled as needed.

Many patients report improved bladder control and pelvic floor strength after the first few sessions, with optimal results usually felt a few weeks after completing the course.

No downtime at all. You can resume your normal activities immediately after each session — including work, exercise, or social plans.

Emsella strengthens your pelvic floor muscles, but just like going to the gym, maintenance is key. Results typically last 6–12 months, depending on your lifestyle and individual factors. Many patients choose occasional top-up sessions to maintain results long-term.

Yes. Emsella is highly effective for male pelvic floor weakness, including post-prostate surgery recovery, urinary leakage, and improving intimate health.

Emsella is FDA-cleared and has no known significant side effects. Some people may experience mild muscle soreness similar to a workout, which quickly subsides.